Mir-488-3p Protects Cardiomyocytes Against Doxorubicin-Induced Cardiotoxicity by Inhibiting CyclinG1
Mingjing Yan,Yuan Cao,Que Wang,Kun Xu,Lin Dou,Xiuqing Huang,Beidong Chen,Weiqing Tang,Ming Lan,Bing Liu,Kaiyi Zhu,Yao Yang,Shenghui Sun,Xiyue Zhang,Yong Man,Mingyan Hei,Tao Shen,Jian Li
DOI: https://doi.org/10.1155/2022/5184135
2022-01-01
Oxidative Medicine and Cellular Longevity
Abstract:Objective. To investigate the protective effects and regulatory mechanism of miR-488-3p on doxorubicin-induced cardiotoxicity. Methods. The C57BL/6 mice and primary cardiomyocytes were used to construct doxorubicin-induced cardiomyocyte injury models in vivo and in vitro. The levels of miR-488-3p and its downstream target genes were analyzed by quantitative real-time PCR. Mouse cardiac function, cell survival, cellular injury-related proteins, and the apoptosis level of cardiomyocytes were analyzed by echocardiography, MTT analysis, Western blotting, and DNA laddering separately. Results. Cardiomyocyte injury caused by a variety of stimuli can lead to the reduction of miR-488-3p level, especially when stimulated with doxorubicin. Doxorubicin led to significant decrease in cardiac function, cell autophagic flux blockage, and apoptosis in vivo and in vitro. The expression of miR-488-3p’s target gene, CyclinG1, increased remarkably in the doxorubicin-treated neonatal mouse cardiomyocytes. Overexpression of miR-488-3p inhibited CyclinG1 expression, increased cardiomyocyte viability, and attenuated doxorubicin-induced cardiomyocyte autophagic flux blockage and apoptosis. Conclusions. miR-488-3p is one of the important protective miRNAs in doxorubicin-induced cardiotoxicity by inhibiting the expression of CyclinG1, which provides insight into the possible clinical application of miR-488-3p/CyclinG1 as therapeutic targets in doxorubicin-induced cardiovascular diseases.